IMAGING CHARACTERISTICS OF HEPATITIS CELL CANCER ASSOCIATED WITH TRANSARTERIAL CHEMOEMBOLIZATION REFRACTORINESS

Do Dang Tan1, Pham Minh Thong2, Trinh Ha Chau1, Vu Dang Luu2, Văn Công Nguyễn3,
1 Radiology Center, Bach Mai Hospital
2 Department of Diagnostic Imaging, Hanoi Medical University
3 Bệnh viện đa khoa tỉnh Ninh Bình

Main Article Content

Abstract

Objectives: Comparison and evaluation of imaging characteristics of hepatocellular carcinoma related to refractoriness of transarterial chemoembolization (TACE). Methods: A descriptive cross-sectional, retrospective study was conducted on 71 patients diagnosed with hepatocellular carcinoma and treated with at least two initial chemoembolization procedures from January 2022 to January 2024 at the Radiology Center of Bach Mai Hospital. The patients were divided into two groups: TACE-resistant and non-TACE-resistant. A comparison and evaluation of demographic, laboratory, and imaging characteristics between the two groups were conducted to identify risk factors for TACE refractoriness. Results: Out of 71 patients, 31 exhibited TACE resistance. Characteristics such as age, gender, risk factors for cirrhosis, and cirrhosis status according to the Child-Pugh classification were not associated with TACE refractoriness. Logistic regression showed that bilobar tumor distribution (OR=4.049, 95% CI [1.323; 9.267], p = 0.0018), >1 tumor (OR=4.052, 95% CI [1.052; 5.266], p = 0.043), and beyond the up-to-7 criteria (OR=3.555, 95% CI [1.201; 7.284], p = 0.026) were associated with TACE refractoriness, with a model predictive accuracy of 74.6%. Conclusion: Imaging characteristics such as bilobar tumor distribution, more than 3 tumors, and beyond up-to-7 criteria are independent risk factors that increase the likelihood of TACE refractoriness

Article Details

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. doi:10.3322/caac.21834
2. Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
3. Wang TC, An TZ, Li JX, Zhang ZS, Xiao YD. Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. Front Mol Biosci. 2021;8:633590. doi:10.3389/fmolb.2021.633590
4. Kudo M, Kawamura Y, Hasegawa K, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10(3):181-223. doi:10.1159/000514174
5. Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. In: StatPearls. StatPearls Publishing; 2024. Accessed August 7, 2024. http://www.ncbi.nlm.nih.gov/books/NBK559177/
6. Yang C, Luo Y gen, Yang H cai, Yao Z hang, Li X. Effects of Early TACE Refractoriness on Survival in Patients with Hepatocellular Carcinoma: A Real-World Study. Journal of Hepatocellular Carcinoma. 2022;9:621-631. doi:10.2147/JHC.S373112
7. Zou ZM, An TZ, Li JX, Zhang ZS, Xiao YD, Liu J. Predicting early refractoriness of transarterial chemoembolization in patients with hepatocellular carcinoma using a random forest algorithm: A pilot study. J Cancer. 2021;12(23):7079- 7087. doi:10.7150/jca.63370
8. Koroki K, Ogasawara S, Ooka Y, et al. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer. 2020;9(5):596-612. doi:10.1159/000508809